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ABSTRACT OF THESIS 
Functional Analysis of a Critical Glycine (Glycine 12) in Beta-type  
Connexins of Human Skin  
 
At least five beta-type connexins are expressed in various layers of the skin (Cx26, Cx30, Cx30.3, 
Cx31, and Cx32) and all include a glycine residue at position 12.  Glycine12 (G12) is located about 
halfway through the cytoplasmic amino terminus and has been the focus of several studies related 
to connexin diseases and gap junction channel structure. The importance of this residue is evident 
in the severity and diversity of diseases associated with amino acid substitutions at G12 including 
hereditary forms of skin disease, deafness and neuropathy. This study uses bioinformatic analysis 
in combination with mutational analysis and electrophysiology to better understand the importance 
of G12. Sequence alignments revealed that G12 is one of only three conserved glycine residues in 
beta-type connexins of skin.  The functional consequences of mutations at position G12 were 
investigated through expression and characterization in Xenopus oocytes.  Three disease-
associated mutants were created and expressed including Cx31G12D, Cx31G12R and Cx32G12S. 
Cx31G12D induced cell death through a mechanism that was mildly calcium-sensitive.  
Cx31G12R and Cx32G12S drastically reduced the formation of functional intercellular channels.   
These data are consistent with other studies reporting a variety of functional consequences when 
G12 is altered in beta-type connexins.   
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Introduction 
Overview of Gap Junction Structure and Function   
Gap junctions are gated intercellular channels that form narrow pores allowing the exchange of 
ions, metabolites and signaling molecules between cells (Berg et al., 2002). Each gap junction 
channel is comprised of two hemichannels (connexons) and each hemichannel involves a 
hexameric arrangement of subunit proteins around a central pore (Berg et al. 2002).  The connexin 
family of transmembrane proteins assemble to form vertebrate gap junctions, while innexin 
proteins assemble to form invertebrate junctions (Lodish et al., 2004).   Connexins are named 
according to their predicted molecular weight.  For example connexin31 (Cx31) has a predicted 
molecular weight of 31 kilodaltons while connexin26 (Cx26) has a predicted molecular weight of 
26 kilodaltons (Berg et al., 2002).  
 
There are 21 different human connexins encoded in the human genome (Laird, 2006).  While it is 
it is clear that connexins are expressed in specific but overlapping patterns knowledge of their 
expression patterns and functions is continually being refined (Scott and Kelsell, 2011).  
Connexins share a common membrane topology but have unique amino acid sequences, 
permeability, gating patterns and sites for regulation (Harris, 2001) reflecting their diverse 
functions. The standard connexin topology includes four transmembrane domains (M1-M4), 
cytoplasmic amino and carboxyl termini, and two extracellular loops (Figure 1).   
 
Each gap junction channel is composed of twelve connexins, six from one cell and six from its 
communicating partner.  The six connexins contributed by each cell are arranged around a central 
pore forming a connexon, or hemichannel (Figure 2A).   Connexon hemichannels generally 
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remain closed until they dock with a connexon in an adjacent cell, however physiological roles for 
hemichannels are being discovered each year (Goodenough and Paul, 2003).    
 
The genes encoding connexins are classified into groups based on evolutionary origin and 
sequence similarity (Hsieh et al., 1991). Most of the smaller connexins, for instance Cx26, Cx31 
and Cx32 are grouped together as beta-type connexins (Figure 2B) and their gene names reflect 
this categorization (eg. GJB2, GJB3, and GJB1 respectively). The numbers are assigned based on 
the order in which the genes were identified.  For instance Cx32 and Cx43 were two of the first 
connexins to be identified and this is reflected by the gene names GJB1 and GJA1 respectively 
(Willecke et al., 2002).    
 
Focus on the Amino Terminus 
Of the 21 connexins in the human genome there are currently high-resolution atomic models for 
three: Cx26, Cx46 and Cx50 (Maeda et al., 2009; Bennett et al., 2016; Myers et al., 2018).   
Structural data related to Cx26 (Maeda et al., 2009; Bennett et al., 2016) is the best representation 
of beta-type connexins.   A side-view of the Cx26 pore as determined by Maeda et al., (2009) is 
shown in Figure 3.  The N-terminus (NT) is highlighted in red and can been seen lying adjacent 
to the channel wall, folded into the pore.  This data is consistent with an earlier cryo-EM structure 
of a gap junction channel composed of Cx26 that revealed a “plug” in the vestibule of the channel 
(Oshima et al., 2007) lending support to the hypothesis that the NT folds into the channel.   Other 
studies have provided information about the structure and function of the NT using site-directed 
mutagenesis, expression in cell lines, dye transfer assays, electrophysiology and nuclear magnetic 
resonance (NMR).  These studies suggest that the NT is important for protein trafficking, 
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oligomerization and channel gating (Verselis et al., 1994; Purnick et al., 2000a; Kyle et al., 2008; 
Kalmatsky et al., 2012).  The N-terminus of Cx26 has also been studied as an independent peptide 
using nuclear magnetic resonance (Purnick et al., 2000b). The structure revealed a flexible hinge 
flanked by two helical domains suggesting a “domain-hinge-domain” model of NT placement 
within the mouth of the pore.  It was proposed that a turn involving residues 12-15 acts as the 
hinge, with residues 1-10 positioned in the channel entrance.  Mutations that disrupt the open turn 
as visualized by NMR also disrupt channel function (for example, G12S, G12Y, and G12V). 
 
 
Skin Disease and Mutations of the Glycine Residue G12 
Connexin mutations underlie a wide range of hereditary disorders including cataracts, deafness 
and skin disease (Laird, 2006).  Several different skin disorders are cause by connexin mutations  
(Mese et al., 2007). Figure 4 shows a cross section of human skin identifying major layers of the 
skin and highlighting the beta-type connexins such as connexin26, connexin30, connexin30.3, 
connexin31, connexin31.1 and connexin32 (Di et al., 2001; Mese et al., 2007).  These connexins 
of skin are discussed below with particular focus on skin disease and point mutations occurring at 
G12.  While mutations inducing amino acid substitution of G12 represent a small subset of the 
mutations associated with skin disease they occur in a number of connexins and are linked to 
several skin diseases (Table 1). 
 
Connexin26 (GJB2)  Mutations in the gene encoding connexin26 were first associated with 
hereditary skin disorders in 2002 when mutations in the cytoplasmic domains and first extracellular 
loop were associated with keratitis-ichthyosis-deafness (KID) syndrome (Richard et al., 2002).  
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KID syndrome was first identified in 1981 by Skinner and colleagues and is a rare hereditary 
disorder related to development of stratifying epithelium that affects the skin and also causes 
sensorineural hearing loss. The gene encoding Cx26 (GJB2) was identified as a gene associated 
with sensorineural hearing loss (Kelsell et al., 1997) with up to 50% of non-syndromic deafness 
cases caused by defects in GJB2 (Denoyelle et al., 1999).   Only a subset of deafness mutations 
also cause skin disease.  One of those mutations is G12R (Lazic et al., 2012) which causes 
symptoms of KID syndrome. In addition, the hereditary mutation Cx26G12V was associated with 
deafness but not skin disease when found in patients heterozygous for GJB2 mutations (Kenna et 
al., 2001).  This demonstrates that the nature of an amino acid substitution induced by a hereditary 
mutation can effect physiology and also highlights the importance of understanding the functional 
consequences of specific mutations.   
 
Connexin30 (GJB6)  Mutations in the gene encoding connexin30 are also linked to deafness and 
to skin disease (Bitner-Glindzic, 2002).  The primary skin condition is known as Clouston 
syndrome, a disorder that affects hair, teeth, nails and skin (Lamartine et al., 2000).  Thus far 
mutations of the glycine residue G12 have not been reported in Cx30 however mutation at an 
adjacent glycine (G11) is implicated in Clouston syndrome (Chen et al., 2010).  Glycine occurs at 
position 11 in only two of the beta-type skin connexins (Cx26 and Cx30) while other beta-type 
connexins of skin include serine at position 11 (eg. S11, G12).  
 
Connexin30.3 (GJB4) Mutations in the gene encoding connexin30.3 are linked to the hereditary 
skin disease erythrokeratoderma variabilis (EKV) (Richard et al., 2003) a disease characterized by 
transient erythema and hyperkeratosis. Palmoplantar keratoderma is present in some patients and 
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in most cases the phenotype is apparent within the first year of an infant’s life A number of point 
mutations have been identified in families presenting with EKV including the missense mutation 
G12D  (Richard et al., 2003; Van Steesel et al., 2009).   
 
Connexin31 (GJB3)  Mutations in the gene encoding connexin31 were the first connexin 
mutations linked to hereditary skin disease (Richard et al., 1998).  Mutations in the gene encoding 
connexin31 have also been linked to hereditary deafness and neuropathy (Lopez-Bigas et al., 
2001). So far two EKV mutations have been identified at position G12 in Cx31: G12D (Rouan et 
al., 2003) and G12R (Diestel et al., 2002; He et al., 2005).   
 
Connexin31.1 (GJB5) The gene encoding connexin31.1 was associated with skin physiology 
when it was found to be expressed in skin and inner ear (Xia et al., 1998).  However, mutations in 
Cx31.1 were associated with deafness but not skin disease and no mutations have so far been 
identified at position G12. 
  
Connexin32 (GJB1)  Hereditary mutations in the gene encoding connexin32 were first associated 
with a neurodegenerative disease known as Charcot-Mare Tooth Disease (CMTX) (Bergoffen et 
al., 1993). Charcot-Marie-Tooth disease type X (CMTX) is a demyelinating disease associated 
disruption of myelin. Cx32 forms channels between layers of the myelin sheath which provide a 
radial diffusion pathway for metabolites and nutrients. Over 160 CMTX-associated mutations in 
the Cx32 gene have been identified (Bone et al., 1997).  One of these involves an amino acid 
substitution at position 12 (G12S) (Bone et al., 1997; Abrams et al., 2001).  Thus far there have 
6 
 
been no skin diseases associated with mutations in Cx32, likely because it is expressed at low 
levels and only in specific types of skin (eg. the palm, Di et al., 2005).  
 
Critically Positioned Glycine 
The conservation of glycine at the 12th position of beta-type connexins is speculated to play a 
pivotal role in channel function.  Glycine is the smallest amino acid, lacking a side chain.  It often 
facilitates turns or bends in protein structures (Marcelino and Gierasch, 2008).  It was previously 
demonstrated by NMR that the amino terminus of connexins forms an open turn and that the turn 
was retained when glycine was replaced by proline but not other amino acids (eg. G12S, G12Y, 
G12P) (Kalmatsky et al., 2009). The open turn involves a reversal in the direction of the 
polypeptide chain. Glycine facilitates the turn based on its flexibility whereas proline induces a 
turn because of its cyclic structure. It was also demonstrated that of several amino acid 
substitutions at G12 only the G12P mutant formed functional channels (Kalmatsky et al., 2012).  
  
Summary 
The goal of this project was to investigate the role of G12 with focus on beta-type connexins 
expressed in skin.  The conserved nature of G12 was examined through sequence analysis followed 
by a literature review of hereditary mutations at position12 in beta-type connexins of human skin.  
Experimental work focused on Cx31 (G12D and G12R) and Cx32 (G12S).  Mutants were created 
using site-directed mutagenesis, RNA encoding wildtype and mutant proteins was transcribed in 
vitro and injected into Xenopus oocytes. Electrophysiological recordings were performed in single 
and paired Xenopus oocytes.  
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Methods 
Sequence Analysis  
Connexin sequences were obtained from Genbank (National Center for Biotechnology 
Information).  All sequences used represent Homo Sapiens.  Reference numbers, complete gene 
sequences, and amino acid sequences are included in Table 2.  Amino acid sequences were aligned 
using MPI Bioinformatics Toolkit (Zimmerman et al., 2018) specifically MAFFT software 
(Multiple alignment program for amino acid or nucleotide sequences (MAFFT v7; 
http://mafft.cbrc.jp/alignment/software/). 
 
Creation of Mutants 
The human Cx31 gene was a gift of Dr. David Kelsell (Barts and the London College of Medicine) 
subcloned into a Xenopus oocyte expression vector by Shelby Rarick (Buffalo State Honors 
Thesis).  The rat Cx32 gene was a gift from Dr. Bruce Nicholson (University of Texas Health 
Science Center at San Antonio). General features of the oocyte expression vectors are shown in 
Figure 5. Site-directed mutagenesis was performed using the Quikchange Lightning Site-Directed 
Mutagenesis kit (Agilent Technologies, Santa Clara, CA).  The Agilent Technologies company 
website includes a primer design program that was used to create mutagenic primers.  Mutagenic 
primers are typically 20 to 30 base pairs in length and incorporate single codon changes, being 
complementary to the gene sequence in the target region but incorporating changes necessary to 
substitute a single amino acid.  For mutagenesis both forward and reverse primers are required, 
and they are complementary to one another.  Primers were ordered from IDT (Integrated DNA 
Technologies, Newark NJ).  Mutagenesis reactions were placed in a thermocycler and 
programmed to 18 cycles with temperatures for denaturing (98 °C), annealing (50°C) and 
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elongation (74°C).  The final step of mutagenesis involves addition of a restriction enzyme, DpnI, 
to digest parental DNA.  After digestion of parental DNA it is expected that most remaining 
plasmids contains the desired mutation.  However each plasmid has the potential to be either 
parental (nonmutated DNA), mutated (mutation) or neither (a PCR-based error).   DNA must 
therefore be sequenced.  Prior to sequencing, the Dpn1-digested plasmid DNA is used to transform 
competent cells, which are grown overnight on the selective media.  The following transformation 
procedure was used: Two microliters of the digested plasmid DNA will be added to 50 microliters 
of XL-1 supercompetent cells for the transformation reaction. The reaction was incubated on ice 
for 30 minutes then heat pulsed at 42 °C for 45 seconds and then placed on ice again for 2 minutes. 
A specialized S.O.C broth (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, and 20 mM glucose) was added to the reaction and then incubated for 1 
hour in a shaking incubator at 220 rpm. After the incubation, the transformed bacteria was plated 
on LB + AMP plates.  One liter of LB + AMP was prepared using 20 g bacto-tryptone, 5 g yeast 
extract, 10 g NaCl, 100 µg/ml ampicillin.  Plates included 1% bactoagar.)  Plates were incubated 
at 37 °C overnight. The following day, colonies were selected, each colony representing one of the 
three possible types of plasmid.  Three or four colonies were selected, used to inoculate growth 
media (LB+ AMP) and grown overnight for amplification.    A 1.5% agarose gel was run at 75 V 
and stained with ethidium bromide to confirm the presence of plasmid DNA prior to sequence 
analysis.  The DNA was compared to a DNA ladder (Zip Ruler1, Fermentas Inc.) The following 
day plasmid DNA was isolated using a Qiagen SpinPrep Kit (Qiagen Inc, Redwood City CA) and 
sent to Genscript USA (Piscataway NJ) after using gel electrophoresis to confirm quantity and 
quality of the DNA.  Of the total 50 µl eluted in the final step of plasmid isolation, 10 µl was sent 
for sequence analysis.   The remaining DNA was stored at -20 ° C.  
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The promoter for RNA polymerase varied for different constructs and the information is 
summarized in Table 3.  These promoters also served as the priming sites for sequencing using 
Genscript’s in-house primers.  Genes were sequenced through all or most of the coding region 
Once a sequence was retrieved it was translated and the amino acid sequence was compared to the 
wild-type amino acid sequence to confirm both the mutation and the remaining sequence.   
 
In vitro transcription.     
Prior to in vitro transcription plasmid DNA were linearized using restriction enzymes.  Restriction 
enzymes were construct-specific and are summarized in Table 3.  Linearized DNA was 
precipitated using 0.5 M EDTA, ethanol and sodium acetate. DNA was precipitated in a microfuge 
tube at -20°C for approximately 24 hours. Then the precipitate was centrifuged for 30 minutes at 
13,000 rpm and DNA was suspended in 6µl nuclease-free water. The linearized DNA was 
analyzed by gel electrophoresis on a 1% agarose gel.  The mMessage mMachine In Vitro 
Transcription Kit (Thermofisher, Grand Island, NY) was used to create RNA.  Reactions included 
10 µl Nucleotide Mix, 2 µl RNA polymerase, 8 µl template DNA and 2.2 µl reaction buffer.  
Reactions were incubated at 37°C for 2 hours. Following incubation, the RNA was precipitated 
using the LiCl method.  This involved adding 20 µl nuclease free water and 50 µl of LiCl to the 
reaction and incubated overnight at -20°C.  The following day the samples were centrifuged at 
13,000 rpm in a 4 °C centrifuge for 20 minutes.  A small RNA pellet was often apparent.  It was 
washed with 70% ethanol and then resuspended in 10 µl of nuclease free water.   Resuspended 
RNA was analyzed by gel electrophoresis to confirm quality and quantity.  1µl of RNA was 
combined with loading dye and run alongside an RNA control (Control 250 Ambion Inc.) on a 1% 
agarose gel for 15 minutes at 100 volts to estimate concentration (125 ng/µl).  
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Handling and Injection of Oocytes  
Xenopus oocytes were used as an expression system to compare the characteristic of wildtype and 
mutated connexins. Surgical removal of oocytes from female Xenopus laevis frogs was conducted 
following a Buffalo State IACUC-approved protocol. After removal, oocytes were placed in OR2 
solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM Tris base, pH 7. 20 supplemented with 
20 mg/ml of streptomycin sulfate, penicillin G, and gentamicin sulfate (Sigma Chemical, St. Louis, 
MO).  The frog was sutured and placed in shallow water to recover.  The follicle layer surrounding 
the oocytes was partially digested using Type 1A collagenase (Sigma Chemical, St. Louis MO), 
typically about 70 mg dissolved in 10 ml of OR2 for 20 minutes with continuous rocking.  The 
collagenase was removed by washing several times with fresh OR2 media before the oocytes were 
placed in MB1 media (88 nM NaCl, 1 mM KCl, 0.41 mM CaCl2 0.82 mM, 1 mM MgCl2, 2.4 mM 
NaHCO3, 0.33 mM Ca(NO3)2, 20 mM HEPES pH 7.4 with NaOH, supplemented with 20 mg/ml 
of streptomycin sulfate, penicillin G, and gentamicin sulfate (antibiotics from Sigma Chemical, St. 
Louis, MO)  
 
Injection and Recording from Xenopus Oocytes  
Any remaining follicle layer was manually removed with fine forceps before oocytes were injected 
with 0.5 ng of antisense oligonucleotide directed against XeCx38 to eliminate endogenous 
Xenopus connexins (Genetools Inc, Philamel, OR).  The following day RNA encoding the 
connexin of interest was injected (5 ng per oocyte, 41 nl volume unless otherwise stated).  For 
recordings from single oocytes, the vitelline layer was retained and recordings were performed the 
following day.  For intercellular recordings from paired oocytes, the vitelline layer was removed 
12-24 hours after injection and the oocytes were paired together in shallow agar wells.  A typical 
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voltage clamp experiment involving single cells involved measurement of currents while the 
oocyte was maintained at -40 mV between pulses to more positive and negative membrane 
potentials.  A typical voltage clamp experiment involving paired oocytes involved continuous 
clamping of one cell at -20 mV while its partner is pulsed to induce transjunctional voltages of 
±100 mV. Example output from four channels during a dual cell voltage clamp experiment is 
shown in Figure 6.  The current measured in the clamped cells is the junctional current.  
 
Survivorship Assays 
In some cases a survivorship experiment was conducted to measure the health of oocytes over 
time. Oocytes were injected with RNA diluted to 75 ng/ul or 125 ng/µl and placed in a petri dish 
filled with solution.  Three treatment solutions were used: MB1, MB1 + 2 mM CaCl2 and MB1+ 
1mM CoCl2. Oocytes were monitored every 4 to 8 hours for changes in phenotype at whch time 
they were scored as healthy (no change from uninjected appearance), dying (blotchy and/or overly 
turgid), or dead (ruptured).  
 
Data Analysis and Presentation 
Survivorship data was analyzed and plotted using Microsoft Excel   A line graph was created to 
view the time-dependent changes in the number of healthy oocytes.   Voltage-clamp recordings 
were analyzed using Clampfit software (Molecular Devices, San Jose, CA) and Origin Software 
(OriginLab Corporation, Northampton, MA).  Intercellular currents were displayed as current 
traces resulting from 10 mV voltage pules.   Single oocyte recordings were presented in plots of 
current-versus voltage (I-V curves) using Origin Software (OriginLab Corporation, Northampton, 
MA).   
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Results 
 
Amino Acid Alignments 
The amino acid sequences of five beta-type connexins expressed in human skin were obtained 
from NCBI and aligned using Clustal (MPI Bioinformatics Toolkit).  The alignment revealed the 
conserved glycine at position 12 as well as two other conserved glycine residues (Figure 7).  G12 
is located about halfway through the amino terminus while the two other conserved glycines are 
located in the extracellular loops.  
 
Diseases Associated with Mutations at G12  
The importance of G12 in gap junction channels is demonstrated by the number of mutations at 
this site associated with genetic diseases. Table 1 shows a summary of G12 mutations in the five 
beta-type connexins examined in this study and the diseases associated with them.  Thus far 
mutations at G12 have been identified in three of the beta-type connexins, Cx26, Cx30.3 and Cx31.  
Interestingly they cause slightly different skin disorders, and one of the Cx26 mutations (G12V) 
does not cause skin disease but causes deafness.   
 
Cx31G12D Induces Cell Death 
The first mutant to be created and tested in oocytes was Cx31G12D.  During the first couple of 
attempts to test gap junction function it was noticed that oocytes injected with RNA encoding 
Cx31G12D were susceptible to loss of polarization followed by bursting or rupturing. To 
demonstrate this experimentally oocytes were observed for 72 hours and the percentage of 
surviving oocytes was plotted (Figure 8).  Two different concentrations of RNA (for both mutant 
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and wildtype) were injected into oocytes.  These were referred to as full strength RNA (125 ng/µl 
≈ 5 ng/oocyte) and half strength (67 ng/µl ≈ 2.5 ng/oocyte ).   Oocytes were more robust after 
injection of HS- RNA in both cases.  Oocytes injected with FS wildtype Cx31 and Cx31G12D  
had poor health shown by loss of pigmentation in the animal pole.  Twenty-five hours after 
injection 100% of oligo-injected oocytes were healthy but only 50% of those injected with FS 
Cx31 and 70% of those injected with HS Cx31 were healthy.  In the G12D group only a fraction 
of oocytes remained healthy after injection of HS and FS RNA respectively.  The detrimental effect 
of connexin RNA was mildly alleviated by the addition of calcium or cobalt to the media.  Media 
bathing the oocytes included MBI alone or supplemented with calcium (CaCl2, 2 mM) and cobalt 
(CoCl2, 1 mM).  The greatest effect of divalent cations was observed with Cx31 where addition of 
1 mM CoCl2 improved survival at 25 hours to 100% in the HS group.  In the G12D group addition 
of 1 mM CoCl2 improved survival at 25 hours from 20% to 40% in the HS group.   
 
Cx31G12D induces leak currents in single oocytes 
To further assess the mechanism by which Cx31G12D induced cell death two-electrode voltage 
clamp was used assess membrane currents in single oocytes.  Other skin disease mutations (in 
connexins) induce leaky membranes after expression in oocytes and it is hypothesized that 
alteration of gating of single hemichannels may underlie this behavior (Gerido et al., 2007; 
Ambrosi et al., 2013).  Since hemichannels are blocked by divalent cations, addition of calcium 
(or cobalt) is one method of testing the leaky hemichannel hypothesis.  It is also possible to add 
gap junction blockers such as carbenoxolone.  After applying a series of voltage pulses to clamped 
oocytes we observed that oocytes expressing Cx31G12D had larger transmembrane currents than 
oocytes injected with wtCx31 (Figure 9).  Combined with the observations that addition of low 
14 
 
concentrations of divalent cations such as 1 mM CaCl2 enhance survival there is good support for 
a leaky hemichannel mechanism in Cx31G12D.  
 
Cx31G12R and Cx32G12S Induce Small Junctional Currents  
Recording currents from paired oocytes, especially oocytes expressing mutants that are detrimental 
to cell health is challenging.  However recordings were obtained for two of the G12 mutants, 
Cx31G12R and Cx32G12S. Oocytes expressing the mutants exhibited much smaller 
transjunctional currents than oocytes expressing wildtype connexin (Figure 10; Figure 11).  These 
results are consistent with observations that the mutants display trafficking defects because only a 
small percentage of protein may traffic to the plasma membrane resulting in low levels of coupling.   
In terms of junctional currents the Cx31G12R pairings had much lower conductance than those 
from Cx31 (Cx31 WT= 37 µS, Cx31G12R=0.5 µS) and the Cx32G12S pairings had much lower 
conductance than those from Cx32 (Cx32 WT= 17 µS, Cx32 G12S=0.6 µS) 
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Discussion 
After retrieving and translating human connexin sequences retrieved from GenBank,(National 
Center for Biotechnology Information, see Table 2) amino acid alignments were used to confirm 
that glycine is conservatively positioned as the twelfth amino acid within the beta-type connexins 
of skin. A detailed literature review revealed that a number of diseases result from amino acid 
substitutions at position G12 with the following mutations so far identified: Cx26G12R (Lazic et 
al., 2012; Garcia et al., 2016; Taki et al, 2018), Cx30.3G12D (van Steensel et al., 2009), 
Cx31G12D (Rouan et al., 2003), Cx31G12R (He et al., 2005), Cx32G12S (Bergoffen et al., 1993; 
Deng et al., 2019).  In summary, amino acid substitutions at glycine 12 result in skin abnormalities 
when they occur in Cx26, Cx30.3, Cx31 or Cx32. 
 
There has been considerable interest in understanding the role of glycine12 in channel function..  
High resolution gap junction structures depict the N-terminus folded into the cytoplasmic mouth 
of the channel (Oshima et al., 2007; Maeda et al., 2009; Villenelo et al., 2017).  In all cases an N-
terminus bend occurs near or at twelfth residue (Figure 3, Maeda et al., 2009).  Although it is 
theorized that amino acid substitutions at position 12 disrupt gap junction function, specific the 
structural and functional consequences of the mutations warrant further investigation.  Studies 
using NMR to investigate structure of the N-terminus as an independent molecule indicate that the 
consequences of amino acid substitutions are dependent on both the connexin and the amino acid 
substitution (Purnick et al., 2000b; Kalmatsky et al., 2012; Batir et al., 2016).   For instance 
Cx26G12R induces a more flexible bend in the NT whereas Cx32G12R creates a more constricted 
turn.  Functionally Cx26G12R appears to induce leaky channels whereas Cx32G12R fails to form 
functional channels (Batier et al., 2016).  In expression studies Cx31G12D trafficked to the 
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membrane but failed to form functional gap junction channels in HeLa cells (assessed with Flag 
tagged Cx31; Rouan et al., 2003). Other studies showed that the Cx32G12S mutants fail to reach 
the plasma membrane but are trapped in the Golgi apparatus (Martin et al. 2000).  
 
Mutations that disrupt channel function may do so at the level of expression, translation, 
trafficking, oligomerization, docking, gating, or permeability. Expression and analysis of 
individual mutants aims to advance understanding of the outcome and often sheds light on the link 
between a genetic alteration and a physiological disorders.  In some cases, such as CFTR, a highly 
studied chloride channel linked to cystic fibrosis, treatments are tailored to specific mutations 
(Lopes-Pacheco, 2020).  Progress is being made in understanding the mechanisms by which 
connexin mutations cause skin disease, particularly for two of the more highly characterized 
connexins, Cx26 and Cx31.  Some studies report that EKV mutations, including G12D and G12R 
cause cell death and/or alter cell proliferation (Lee et al., 2009; Taki et al., 2018) while others 
report changes in interactions between connexins (Richard et al. 2003).  Mutations that cause cell 
death require more detailed characterization because they could do so by any number of 
mechanisms.  It is possible that disrupting gating mechanisms could result in hemichannels that 
disrupt ion gradients. Gating disruptions could also reflect altered sensitivity to voltage, calcium, 
pH or phosphorylation (Harris, 2001).  It is also possible that altered gating could result in channels 
that dock, forming gap junction channels, but with altered behavior that restricts cell 
communication.  Hence, detailed characterization, using several techniques in a number of 
different expression settings usually required for correct characterization.   
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Fully formed gap junction channels close in response to transjunctional voltage (Vj) and each 
connexin has a characteristic response to Vj (Harris, 2001).   It has previously been shown that 
charged residues in the N-terminus influence the polarity to which connexins respond (Purnik et 
al., 2000a).  However it is not known whether other structural components influence the extent of 
closure in response to Vj, or the voltage to which a response is initiated.  Our results do not suggest 
a role for G12 in gap junction channel gating, and thus far there have not been any published results 
that support this.  However it could be argued that a disruption in the membrane potential is 
suggestive of altered hemichannel behavior, possibly supporting a role for G12 in channel 
regulation (gating). 
 
In our study the mutant Cx31G12D induced cell death through a mechanism that appeared to 
involve leaky membranes.  Oocytes expressing Cx31 and Cx31G12D were partially rescued by 
including 1 mM CoCl2 or 2 mM CaCl2 in the external media suggesting that leaky hemichannels 
may be responsible.  It has been shown that some Cx26 mutants interact with Cx43 when it is 
coexpressed in the same cells and influence gating of Cx43 hemichannels (Shuja et al., 2016).  It 
is possible that Cx31G12D is interacting with an endogenous Xenopus connexin although unlikely 
that XeCx38 is involved since oocytes were injected with morpholino antisense to silence the 
endogenous Cx38.  In an EKV study, investigators transfected Cx31 and mutants in fibroblast cell 
lines (NEB1) found that all of the EKV mutants resulted in cell death and among these mutants 
were G12R and G12S (Di et al. 2005). Recent studies (Lee et al., 2009, Garcia et al., 2018; Taki 
et al., 2018) suggest that Cx26G12R causes leaky hemichannels potentially explaining its role in 
skin pathology.  A recent hypothesis regarding association of Cx26 mutations with skin disease 
and deafness is based on the observation that some mutations induce hemichannel activity.  These 
18 
 
mutations appear to be “gain of function” mutations that cause calcium dysregulation leading to 
skin disease (Shuja et al., 2016).   It is also worth noting that although mutations of G12 have not 
been reported in Cx30, mutation at an adjacent glycine (G11) is implicated in Clouston syndrome 
(Lamartine et al., 2000). 
 
Functional analysis has provided a link between connexin function and skin disease and has 
facilitated generation of several hypotheses regarding connexin function in normal and diseased 
skin.  For instance, Cx31 is expressed in the stratum granulosum, which is comprised of granular 
cells containing keratohyalin granules. At the transition state between stratum granulosum and the 
stratum corneum, granular cells lose their nuclei and organelles and the cells become new 
corneocytes (Ovaere et al. 2009). I hypothesize that Cx31 is a key factor in the transition between 
granular cells and corneocytes. It is possible that granular cells receive a signal to lose their nuclei 
and organelles by means of autocrine or paracrine pathways or via direct communication. One 
protein that potentially regulates this is Cx31. Perhaps the red thickened phenotype of EKV may 
result from granular cells failing to become corneocytes. This hypothesis is worthy of further 
investigation especially promising is the concept that an ointment stimulating gap junction 
intercellular communication could compel the granular cells to become corneocytes..  
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Table 1.  Hereditary Mutations Involving Glycine 12 of Beta-Type Connexins  
Connexin Mutation Hereditary Disease  References  
Cx26 
 
G12V Deafness (non 
syndromic) 
Kenna et al., 2001; 
D’Andrea et al., 2002 
Garcia et al., 2015 
 
 
G12R Keratitis, 
ichthyosis and 
deafness (KID) 
syndrome   
 
Garcia et al, 2015; Taki 
et al, 2018;  Lee et 
al., 2009; Lazic et al., 
2012.  
Cx30.3 G12D Erythrokeratodermia 
variabilis et 
progressiva 
Van Steesel et al., 2009 
Cx31  
 
G12D Erythrokeratodermia 
variabilis et 
progressiva 
Rouan et al., 2003 
G12R  Erythrokeratodermia 
variabilis et 
progressiva 
He et al., 2005 
G12S  Erythrokeratodermia 
variabilis et 
progressive 
 
Deng et al., 2019 
Cx32 G12S X-linked Charcot-
Marie-Tooth disease  
Bone et al., 1997; 
Abrams et al., 2001 
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Table 2.  β-type Connexins ( Homo Sapiens) Expressed in Skin  
 
Cx Ref Nucleotide Amino acid 
26 
(GJB2) 
NM_
0040
04.6 
>NM_004004.6:179-859 Homo sapiens gap junction protein 
beta 2 (GJB2), mRNA 
ATGGATTGGGGCACGCTGCAGACGATCCTGGGGGGTGTGAACAAACACTCCACCAGC
ATTGGAAAGATCTGGCTCACCGTCCTCTTCATTTTTCGCATTATGATCCTCGTTGTG
GCTGCAAAGGAGGTGTGGGGAGATGAGCAGGCCGACTTTGTCTGCAACACCCTGCAG
CCAGGCTGCAAGAACGTGTGCTACGATCACTACTTCCCCATCTCCCACATCCGGCTA
TGGGCCCTGCAGCTGATCTTCGTGTCCACGCCAGCGCTCCTAGTGGCCATGCACGTG
GCCTACCGGAGACATGAGAAGAAGAGGAAGTTCATCAAGGGGGAGATAAAGAGTGAA
TTTAAGGACATCGAGGAGATCAAAACCCAGAAGGTCCGCATCGAAGGCTCCCTGTGG
TGGACCTACACAAGCAGCATCTTCTTCCGGGTCATCTTCGAAGCCGCCTTCATGTAC
GTCTTCTATGTCATGTACGACGGCTTCTCCATGCAGCGGCTGGTGAAGTGCAACGCC
TGGCCTTGTCCCAACACTGTGGACTGCTTTGTGTCCCGGCCCACGGAGAAGACTGTC
TTCACAGTGTTCATGATTGCAGTGTCTGGAATTTGCATCCTGCTGAATGTCACTGAA
TTGTGTTATTTGCTAATTAGATATTGTTCTGGGAAGTCAAAAAAGCCAGTTTAA 
 
>NM_004004.6:179-
859 Homo sapiens 
gap junction 
protein beta 2 
MDWGTLQTILGGVNKHST
SIGKIWLTVLFIFRIMIL
VVAAKEVWGDEQADFVCN
TLQPGCKNVCYDHYFPIS
HIRLWALQLIFVSTPALL
VAMHVAYRRHEKKRKFIK
GEIKSEFKDIEEIKTQKV
RIEGSLWWTYTSSIFFRV
IFEAAFMYVFYVMYDGFS
MQRLVKCNAWPCPNTVDC
FVSRPTEKTVFTVFMIAV
SGICILLNVTELCYLLIR
YCSGKSKKPV 
30 
(GJB6) 
NM_
0013
7009
0.1 
>NM_001370090.1:552-1337 Homo sapiens gap junction 
protein beta 6 (GJB6), transcript variant 5, mRNA 
ATGGATTGGGGGACGCTGCACACTTTCATCGGGGGTGTCAACAAACACTCCACCAGC
ATCGGGAAGGTGTGGATCACAGTCATCTTTATTTTCCGAGTCATGATCCTCGTGGTG
GCTGCCCAGGAAGTGTGGGGTGACGAGCAAGAGGACTTCGTCTGCAACACACTGCAA
CCGGGATGCAAAAATGTGTGCTATGACCACTTTTTCCCGGTGTCCCACATCCGGCTG
TGGGCCCTCCAGCTGATCTTCGTCTCCACCCCAGCGCTGCTGGTGGCCATGCATGTG
GCCTACTACAGGCACGAAACCACTCGCAAGTTCAGGCGAGGAGAGAAGAGGAATGAT
TTCAAAGACATAGAGGACATTAAAAAGCAGAAGGTTCGGATAGAGGGGTCGCTGTGG
TGGACGTACACCAGCAGCATCTTTTTCCGAATCATCTTTGAAGCAGCCTTTATGTAT
GTGTTTTACTTCCTTTACAATGGGTACCACCTGCCCTGGGTGTTGAAATGTGGGATT
GACCCCTGCCCCAACCTTGTTGACTGCTTTATTTCTAGGCCAACAGAGAAGACCGTG
TTTACCATTTTTATGATTTCTGCGTCTGTGATTTGCATGCTGCTTAACGTGGCAGAG
TTGTGCTACCTGCTGCTGAAAGTGTGTTTTAGGAGATCAAAGAGAGCACAGACGCAA
AAAAATCACCCCAATCATGCCCTAAAGGAGAGTAAGCAGAATGAAATGAATGAGCTG
ATTTCAGATAGTGGTCAAAATGCAATCACAGGTTTCCCAAGCTAA 
>NM_001370090.1:55
2-1337 Homo 
sapiens gap 
junction protein 
beta 6 
MDWGTLHTFIGGVNKHST
SIGKVWITVIFIFRVMIL
VVAAQEVWGDEQEDFVCN
TLQPGCKNVCYDHFFPVS
HIRLWALQLIFVSTPALL
VAMHVAYYRHETTRKFRR
GEKRNDFKDIEDIKKQKV
RIEGSLWWTYTSSIFFRI
IFEAAFMYVFYFLYNGYH
LPWVLKCGIDPCPNLVDC
FISRPTEKTVFTIFMISA
SVICMLLNVAELCYLLLK
VCFRRSKRAQTQKNHPNH
ALKESKQNEMNELISDSG
QNAITGFPS 
30.3 
(GJB4)  
NM_
1532
12.3 
>NM_153212.3:372-1172 Homo sapiens gap junction protein 
beta 4 (GJB4), mRNA 
ATGAACTGGGCATTTCTGCAGGGCCTGCTGAGTGGCGTGAACAAGTACTCCACAGTG
CTGAGCCGCATCTGGCTGTCTGTGGTGTTCATCTTTCGTGTGCTGGTGTACGTGGTG
GCAGCGGAGGAGGTGTGGGACGATGAGCAGAAGGACTTTGTCTGCAACACCAAGCAG
CCCGGCTGCCCCAACGTCTGCTATGACGAGTTCTTCCCCGTGTCCCACGTGCGCCTC
TGGGCCCTACAGCTCATCCTGGTCACGTGCCCCTCACTGCTCGTGGTCATGCACGTG
GCCTACCGCGAGGAACGCGAGCGCAAGCACCACCTGAAACACGGGCCCAATGCCCCG
TCCCTGTACGACAACCTGAGCAAGAAGCGGGGCGGACTGTGGTGGACGTACTTGCTG
AGCCTCATCTTCAAGGCCGCCGTGGATGCTGGCTTCCTCTATATCTTCCACCGCCTC
TACAAGGATTATGACATGCCCCGCGTGGTGGCCTGCTCCGTGGAGCCTTGCCCCCAC
ACTGTGGACTGTTACATCTCCCGGCCCACGGAGAAGAAGGTCTTCACCTACTTCATG
GTGACCACAGCTGCCATCTGCATCCTGCTCAACCTCAGTGAAGTCTTCTACCTGGTG
GGCAAGAGGTGCATGGAGATCTTCGGCCCCAGGCACCGGCGGCCTCGGTGCCGGGAA
TGCCTACCCGATACGTGCCCACCATATGTCCTCTCCCAGGGAGGGCACCCTGAGGAT
GGGAACTCTGTCCTAATGAAGGCTGGGTCGGCCCCAGTGGATGCAGGTGGGTATCCA
TAA 
>NM_153212.3:372-
1172 Homo sapiens 
gap junction 
protein beta 4 
MNWAFLQGLLSGVNKYST
VLSRIWLSVVFIFRVLVY
VVAAEEVWDDEQKDFVCN
TKQPGCPNVCYDEFFPVS
HVRLWALQLILVTCPSLL
VVMHVAYREERERKHHLK
HGPNAPSLYDNLSKKRGG
LWWTYLLSLIFKAAVDAG
FLYIFHRLYKDYDMPRVV
ACSVEPCPHTVDCYISRP
TEKKVFTYFMVTTAAICI
LLNLSEVFYLVGKRCMEI
FGPRHRRPRCRECLPDTC
PPYVLSQGGHPEDGNSVL
MKAGSAPVDAGGYP 
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31 
(GJB3) 
NM_
0240
09.3 
>NM_024009.3:591-1403 Homo sapiens gap junction protein 
beta 3 (GJB3), transcript variant 1, mRNA 
ATGGACTGGAAGACACTCCAGGCCCTACTGAGCGGTGTGAACAAGTACTCCACAGCG
TTCGGGCGCATCTGCTGTCCGTGGTGTTCGTCTTCCGGGTGCTGGTATACGTGGTGG
CTGCAGAGCGCGTGTGGGGGGATGAGCAGAAGGACTTTGACTGCAACACCAAGCAGC
CCGGCTGCACCAACGTCTGCTACGACAACTACTTCCCCATCTCCAACATCCGCCTCT
GGGCCCTGCAGCTCATCTTCGTCACATGCCCCTCGCTGCTGGTCATCCTGCACGTGG
CCTACCGTGAGGAGCGGGAGCGCCGGCACCGCCAGAAACACGGGGACCAGTGCGCCA
AGCTGTACGACAACGCAGGCAAGAAGCACGGAGGCCTGTGGTGGACCTACCTGTTCA
GCCTCATCTTCAAGCTCATCATTGAGTTCCTCTTCCTCTACCTGCTGCACACTCTCT
GGCATGGCTTCAATATGCCGCGCCTGGTGCAGTGTGCCAACGTGGCCCCCTGCCCCA
ACATCGTGGACTGCTACATTGCCCGACCTACCGAGAAGAAAATCTTCACCTACTTCA
TGGTGGGCGCCTCCGCCGTCTGCATCGTACTCACCATCTGTGAGCTCTGCTACCTCA
TCTGCCACAGGGTCCTGCGAGGCCTGCACAAGGACAAGCCTCGAGGGGGTTGCAGCC
CCTCGTCCTCCGCCAGCCGAGCTTCCACCTGCCGCTGCCACCACAAGCTGGTGGAGG
CTGGGGAGGTGGATCCAGACCCAGGCAATAACAAGCTGCAGGCTTCAGCACCCAACC
TGACCCCCATCTGA 
>NM_024009.3:591-
1403 Homo sapiens 
gap junction 
protein beta 3 
MDWKTLQALLSGVNKYST
AFGRIWLSVVFVFRVLVY
VVAAERVWGDEQKDFDCN
TKQPGCTNVCYDNYFPIS
NIRLWALQLIFVTCPSLL
VILHVAYREERERRHRQK
HGDQCAKLYDNAGKKHGG
LWWTYLFSLIFKLIIEFL
FLYLLHTLWHGFNMPRLV
QCANVAPCPNIVDCYIAR
PTEKKIFTYFMVGASAVC
IVLTICELCYLICHRVLR
GLHKDKPRGGCSPSSSAS
RASTCRCHHKLVEAGEVD
PDPGNNKLQASAPNLTPI 
31.1 
(GJB5) 
NM_0
0526
8.4 
>NM_005268.4:174-995 Homo sapiens gap junction protein 
beta 5 (GJB5), mRNA 
ATGAACTGGAGTATCTTTGAGGGACTCCTGAGTGGGGTCAACAAGTACTCCACAGCC
TTTGGGCGCATCTGGCTGTCTCTGGTCTTCATCTTCCGCGTGCTGGTGTACCTGGTG
ACGGCCGAGCGTGTGTGGAGTGATGACCACAAGGACTTCGACTGCAATACTCGCCAG
CCCGGCTGCTCCAACGTCTGCTTTGATGAGTTCTTCCCTGTGTCCCATGTGCGCCTC
TGGGCCCTGCAGCTTATCCTGGTGACATGCCCCTCACTGCTCGTGGTCATGCACGTG
GCCTACCGGGAGGTTCAGGAGAAGAGGCACCGAGAAGCCCATGGGGAGAACAGTGGG
CGCCTCTACCTGAACCCCGGCAAGAAGCGGGGTGGGCTCTGGTGGACATATGTCTGC
AGCCTAGTGTTCAAGGCGAGCGTGGACATCGCCTTTCTCTATGTGTTCCACTCATTC
TACCCCAAATATATCCTCCCTCCTGTGGTCAAGTGCCACGCAGATCCATGTCCCAAT
ATAGTGGACTGCTTCATCTCCAAGCCCTCAGAGAAGAACATTTTCACCCTCTTCATG
GTGGCCACAGCTGCCATCTGCATCCTGCTCAACCTCGTGGAGCTCATCTACCTGGTG
AGCAAGAGATGCCACGAGTGCCTGGCAGCAAGGAAAGCTCAAGCCATGTGCACAGGT
CATCACCCCCACGGTACCACCTCTTCCTGCAAACAAGACGACCTCCTTTCGGGTGAC
CTCATCTTTCTGGGCTCAGACAGTCATCCTCCTCTCTTACCAGACCGCCCCCGAGAC
CATGTGAAGAAAACCATCTTGTGA 
>NM_005268.4:174-
995 Homo sapiens 
gap junction 
protein beta 5 
(GJB5) 
MNWSIFEGLLSGVNKYST
AFGRIWLSLVFIFRVLVY
LVTAERVWSDDHKDFDCN
TRQPGCSNVCFDEFFPVS
HVRLWALQLILVTCPSLL
VVMHVAYREVQEKRHREA
HGENSGRLYLNPGKKRGG
LWWTYVCSLVFKASVDIA
FLYVFHSFYPKYILPPVV
KCHADPCPNIVDCFISKP
SEKNIFTLFMVATAAICI
LLNLVELIYLVSKRCHEC
LAARKAQAMCTGHHPHGT
TSSCKQDDLLSGDLIFLG
SDSHPPLLPDRPRDHVKK
TIL 
32 
(GJB1) 
NM_0
0109
7642  
 
>NM_001097642.2:96-947 Homo sapiens gap junction protein 
beta 1 (GJB1), transcript variant 1, mRNA 
ATGAACTGGACAGGTTTGTACACCTTGCTCAGTGGCGTGAACCGGCATTCTACTGCC
ATTGGCCGAGTATGGCTCTCGGTCATCTTCATCTTCAGAATCATGGTGCTGGTGGTG
GCTGCAGAGAGTGTGTGGGGTGATGAGAAATCTTCCTTCATCTGCAACACACTCCAG
CCTGGCTGCAACAGCGTTTGCTATGACCAATTCTTCCCCATCTCCCATGTGCGGCTG
TGGTCCCTGCAGCTCATCCTAGTTTCCACCCCAGCTCTCCTCGTGGCCATGCACGTG
GCTCACCAGCAACACATAGAGAAGAAAATGCTACGGCTTGAGGGCCATGGGGACCCC
CTACACCTGGAGGAGGTGAAGAGGCACAAGGTCCACATCTCAGGGACACTGTGGTGG
ACCTATGTCATCAGCGTGGTGTTCCGGCTGTTGTTTGAGGCCGTCTTCATGTATGTC
TTTTATCTGCTCTACCCTGGCTATGCCATGGTGCGGCTGGTCAAGTGCGACGTCTAC
CCCTGCCCCAACACAGTGGACTGCTTCGTGTCCCGCCCCACCGAGAAAACCGTCTTC
ACCGTCTTCATGCTAGCTGCCTCTGGCATCTGCATCATCCTCAATGTGGCCGAGGTG
GTGTACCTCATCATCCGGGCCTGTGCCCGCCGAGCCCAGCGCCGCTCCAATCCACCT
TCCCGCAAGGGCTCGGGCTTCGGCCACCGCCTCTCACCTGAATACAAGCAGAATGAG
ATCAACAAGCTGCTGAGTGAGCAGGATGGCTCCCTGAAAGACATACTGCGCCGCAGC
CCTGGCACCGGGGCTGGGCTGGCTGAAAAGAGCGACCGCTGCTCGGCCTGCTGA 
M>NM_001097642.2:9
6-947 Homo sapiens 
gap junction 
protein beta 1 
MNWTGLYTLLSGVNRHST
AIGRVWLSVIFIFRIMVL
VVAAESVWGDEKSSFICN
TLQPGCNSVCYDQFFPIS
HVRLWSLQLILVSTPALL
VAMHVAHQQHIEKKMLRL
EGHGDPLHLEEVKRHKVH
ISGTLWWTYVISVVFRLL
FEAVFMYVFYLLYPGYAM
VRLVKCDVYPCPNTVDCF
VSRPTEKTVFTVFMLAAS
GICIILNVAEVVYLIIRA
CARRAQRRSNPPSRKGSG
FGHRLSPEYKQNEINKLL
SEQDGSLKDILRRSPGTG
AGLAEKSDRCSAC 
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Table 3.  Connexin Constucts and Molecular Biology of Mutagenesis 
Connexin Species Vector Restriction 
enzyme * 
Priming 
site RNA 
Pol 
Gift from 
Cx31 human pcDNA Xho1 T7 David Kelsell 
Cx32 Rat pGem7zf+ Xba1 SP6 Bruce 
Nicholson 
 linearizes downstream of the connexin gene 
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Figure 1.  Connexin topology showing amino terminus (NT), cytoplasmic loop (CL) and 
cytoplasmic terminus (CT) on the cytoplasmic side of the membrane.  Connexins also have four 
transmembrane domains (TM1-TM4) and two extracellular loops (EL1, EL2).  Handrawn 
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Figure 2.  A) Illustration of connexin oligomerize to form connexons (also known as 
hemichannels) and intercellular channels (gap junction channels).  Six connexins oligomerize 
around a central pore to form a connexon.  An intercellular channel is formed when two connexons 
dock together (from Goodenough and Paul, 2003).  B) Grouping of connexins into families is 
dependent on sequence, and can provide a basis for anticipated interactions.  Connexins targeted 
in this study lie within the beta-family (ß) and are expected to interact heteromerically and 
heterotypically (from Bosco et al., 2011) 
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Figure 3.  Structure of a Cx26 gap junction channel pore with selected amino acids labelled. 
Cytoplasmic face is top where the pore is widened.  Only half of a channel is shown in this image 
Relevant to this study is the position of G12 which resides near a bend in the amino terminus (NT, 
red). NT folds into the pore and interacts closely with the first transmembrane domain (TM1).  
Transmembrane domains are shown in blue and extracellular loops are green. (from Maeda et al., 
2009).   
 
 
 
 
 
 
 
 
33 
 
 
 
 
 
 
 
Figure 4.  Illustration of human skin showing distinct layers that develop as cells progress and 
differentiate from the basale to the corneal layers.  At least nine connexins are expressed in skin 
in specific but overlapping patterns.  The beta-type connexins Cx26, Cx30, Cx30.3, Cx31 are co-
expressed in the stratum granulosom.  Cx32 is also expressed at low levels in the granular layer of 
palmar skin (Di et al., 2005).  (image from Mese et al., 2007)  
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Figure 5.  Vectors used for connexin expression in oocytes include several standard features.  
Although the connexin genes have been subcloned into a variety of different vectors each vector 
includes sequences for selection which in all cases conferred ampicillin resistance, a promoter for 
RNA polymerase that is located upstream of the 5’ region of the connexin gene (eg. T7, SP6 or 
T3) and a restriction site used to linearize the plasmid downstream of the 3’ end of the gene prior 
to in vitro transcription.   
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Figure 6.  Example of four channels recorded during dual cell two-electrode voltage clamp.  
Voltage is clamped in both cells and current is recorded.  Voltage is controlled by an amplifier 
and computer program.  Junctional currents are recorded from the cell that is clamped at a 
constant voltage while voltage in the adjacent cell is changed.  In this configuration the only 
voltage gradient induced in that cell occurs across the junction.  TOP LEFT: voltage in the 
pulsed cell.  TOP RIGHT: voltage in the clamped cell often involves a series of voltage steps to 
induce progressively higher voltages across the junction.  A small pre-pulse is often included to 
demonstrate stability of the recording.  BOTTOM LEFT: current in the pulsed cell (combination 
of junctional and transmembrane currents).  BOTTOM RIGHT: current in the clamped cell 
(junctional current).  Junctional currents decay in time- and voltage-dependent manner (from 
Skerrett et al., 2001) 
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Figure 7.  Amino acid alignment of five beta-type connexins expressed in human skin.  Conserved 
glycine residues are highlighted in red and the amino terminus is shaded blue.  Sequences were 
aligned using Clustal (MPI Bioinformatics Tools). 
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Figure 8.  Oocyte survival after injection of RNA encoding Cx31 (top) or Cx31G12D (bottom).   
After injection of RNA oocytes was observed for 72 hours and the percentage of surviving oocytes 
was plotted.   Approximately 15 oocytes were included in each group.  Negative control is “oligo” 
indicating that oocytes received only morpholino against XeCx38.  Media bathing the oocytes 
included MBI alone or supplemented with calcium (CaCl2, 2 mM) and cobalt (CoCl2 1 mM).  In 
addition RNA was tested at 125 ng/ul (about 5 nm per oocyte, FS) and 65 ng/ul (about 2.5 ng per 
oocyte HS)  
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Figure 9.  Cx31G12D induces membrane currents in single oocytes.  Current versus voltage plots 
for Cx31G12D and wildtype Cx31 demonstrate that the mutant G12D increases membrane 
permeability. Currents were induced by voltage pulses from a holding potential of -20 mV to +60 
and then -160 mV in 20 mV increments. N = 3.   
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Figure 10.  Gap junction intercellular currents recorded from paired Xenopus oocytes expressing 
Cx31 (TOP) or Cx31G12R (LOWER). After injection of RNA (125 ng/ul) the vitelline layers were 
removed and oocytes were paired overnight.  Currents were recorded in a continuously clamped 
oocyte while its partner was pulsed in 20 mV increments to induce Vj’s up to +100 mV and -100 
mV.  Data was collected by Adedoyin Akingbade who was an undergraduate student working 
under my guidance at the time of the recordings.  
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Figure 11.  Gap junction intercellular currents recorded from paired Xenopus oocytes expressing 
Cx32 (TOP) or Cx32G12S (LOWER). After injection of RNA (125 ng/ul) the vitelline layers were 
removed and oocytes were paired overnight.  Currents were recorded in a continuously clamped 
oocyte while its partner was pulsed in 20 mV increments to induce Vj’s up to +100 mV and -100 
mV.   
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